Novartis Highlights Leukemia Drug Tasigna


October 20, 2009

The Wall Street Journal

ZURICH -- Novartis AG said its leukemia drug Tasigna worked better than the company's older product Gleevec in a clinical trial, underpinning expectations that Novartis is positioning Tasigna to replace Gleevec when the latter drug loses patent protection in 2015... Read More (access limited)